| Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised … Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with ... The Lancet 372 (9644), 1174-1183, 2008 | 1229 | 2008 |
| Diurnal rhythms of serum total, free and bioavailable testosterone and of SHBG in middle‐aged men compared with those in young men MJ Diver, KE Imtiaz, AM Ahmad, JP Vora, WD Fraser Clinical endocrinology 58 (6), 710-717, 2003 | 401 | 2003 |
| Sensitivity and specificity of photography and direct ophthalmoscopy in screening for sight threatening eye disease: the Liverpool Diabetic Eye Study SP Harding, DM Broadbent, C Neoh, MC White, J Vora Bmj 311 (7013), 1131-1135, 1995 | 350 | 1995 |
| Incidence of sight-threatening retinopathy in patients with type 2 diabetes in the Liverpool Diabetic Eye Study: a cohort study N Younis, DM Broadbent, JP Vora, SP Harding The Lancet 361 (9353), 195-200, 2003 | 303 | 2003 |
| Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia AH Barnett, P Mackin, I Chaudhry, A Farooqi, R Gadsby, A Heald, J Hill, ... Journal of Psychopharmacology 21 (4), 357-373, 2007 | 246 | 2007 |
| Renal hemodynamics in newly presenting non-insulin dependent diabetes mellitus JP Vora, J Dolben, JD Dean, D Thomas, JD Williams, DR Owens, ... Kidney international 41 (4), 829-835, 1992 | 224 | 1992 |
| Cost effectiveness analysis of screening for sight threatening diabetic eye disease M James, DA Turner, DM Broadbent, J Vora, SP Harding Bmj 320 (7250), 1627-1631, 2000 | 218 | 2000 |
| A review of modern insulin analogue pharmacokinetic and pharmacodynamic profiles in type 2 diabetes: improvements and limitations M Evans, PM Schumm‐Draeger, J Vora, AB King Diabetes, Obesity and Metabolism 13 (8), 677-684, 2011 | 184 | 2011 |
| Effect of ruboxistaurin in patients with diabetic macular edema: thirty-month results of the randomized PKC-DMES clinical trial PKC-DMES study group Archives of ophthalmology (Chicago, Ill.: 1960) 125 (3), 318-324, 2007 | 170 | 2007 |
| Cutaneous manifestations of the malignant carcinoid syndrome HK Bell, GJ Poston, J Vora, NJE Wilson British Journal of dermatology 152 (1), 71-75, 2005 | 144 | 2005 |
| Study of Once Daily Levemir (SOLVE™): insights into the timing of insulin initiation in people with poorly controlled type 2 diabetes in routine clinical practice K Khunti, T Damci, L Meneghini, CY Pan, JF Yale, SOLVE Study Group Diabetes, Obesity and Metabolism 14 (7), 654-661, 2012 | 140 | 2012 |
| Incidence of sight‐threatening retinopathy in Type 1 diabetes in a systematic screening programme N Younis, DM Broadbent, SP Harding, JP Vora Diabetic Medicine 20 (9), 758-765, 2003 | 139 | 2003 |
| Cardiovascular events and all‐cause mortality associated with sulphonylureas compared with other antihyperglycaemic drugs: AB ayesian meta‐analysis of survival data S Bain, E Druyts, C Balijepalli, CA Baxter, CJ Currie, R Das, R Donnelly, ... Diabetes, Obesity and Metabolism 19 (3), 329-335, 2017 | 131 | 2017 |
| Long-term effects of insulin glargine on the risk of breast cancer S Suissa, L Azoulay, S Dell’Aniello, M Evans, J Vora, M Pollak Diabetologia 54, 2254-2262, 2011 | 131 | 2011 |
| Randomized, multinational, open-label, 2-period, crossover comparison of biphasic insulin aspart 30 and biphasic insulin lispro 25 and pen devices in adult patients with type 2 … L Niskanen, LE Jensen, J Råstam, L Nygaard-Pedersen, K Erichsen, ... Clinical therapeutics 26 (4), 531-540, 2004 | 122 | 2004 |
| Surgery for midgut carcinoid. R Sutton, HE Doran, EMI Williams, J Vora, S Vinjamuri, J Evans, ... Endocrine-Related Cancer 10 (4), 469-481, 2003 | 122 | 2003 |
| Relationship between absorption of radiolabeled soluble insulin, subcutaneous blood flow, and anthropometry JP Vora, A Burch, JR Peters, DR Owens Diabetes Care 15 (11), 1484-1493, 1992 | 117 | 1992 |
| Predictors of the development of microalbuminuria in patients with Type 1 diabetes mellitus: a seven‐year prospective study TMCS Group Diabetic Medicine 16 (11), 918-925, 1999 | 116 | 1999 |
| Insulin degludec versus insulin glargine in type 1 and type 2 diabetes mellitus: a meta-analysis of endpoints in phase 3a trials J Vora, T Christensen, A Rana, SC Bain Diabetes therapy 5, 435-446, 2014 | 113 | 2014 |
| Short-term night-shift working mimics the pituitary-adrenocortical dysfunction in chronic fatigue syndrome G Leese, P Chattington, W Fraser, J Vora, R Edwards, G Williams The Journal of Clinical Endocrinology & Metabolism 81 (5), 1867-1870, 1996 | 113 | 1996 |
Professor Melanie J DaviesDiabetes Research Centre, University of Leicester在 uhl-tr.nhs.uk 的电子邮件经过验证
Professor Melanie J DaviesDiabetes Research Centre, University of Leicester在 uhl-tr.nhs.uk 的电子邮件经过验证